Australia markets close in 55 minutes

Barinthus Biotherapeutics plc (BRNS)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
2.2700+0.0400 (+1.79%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 88.35M
Enterprise value -40.76M
Trailing P/E 6.97
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)108.65
Price/book (mrq)0.47
Enterprise value/revenue -50.83
Enterprise value/EBITDA 0.57

Trading information

Stock price history

Beta (5Y monthly) -0.51
52-week change 30.00%
S&P500 52-week change 325.59%
52-week high 35.1000
52-week low 31.6400
50-day moving average 32.6317
200-day moving average 32.8054

Share statistics

Avg vol (3-month) 324.44k
Avg vol (10-day) 323.11k
Shares outstanding 538.92M
Implied shares outstanding 638.92M
Float 818.37M
% held by insiders 13.69%
% held by institutions 147.85%
Shares short (15 Apr 2024) 414.11k
Short ratio (15 Apr 2024) 40.4
Short % of float (15 Apr 2024) 40.06%
Short % of shares outstanding (15 Apr 2024) 40.04%
Shares short (prior month 15 Mar 2024) 411.89k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-10,024.69%

Management effectiveness

Return on assets (ttm)-20.73%
Return on equity (ttm)-34.15%

Income statement

Revenue (ttm)802k
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)-100.00%
Gross profit (ttm)N/A
EBITDA -78.17M
Net income avi to common (ttm)-73.35M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)142.09M
Total cash per share (mrq)3.65
Total debt (mrq)12.98M
Total debt/equity (mrq)6.94%
Current ratio (mrq)12.45
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-50.92M
Levered free cash flow (ttm)-42.35M